BATS · GSKH
Precidian ETFs Trust GSK plc
Financial Services · Asset Management
$70.91
Up+$0.45 (+0.63%)
Updated Nov 9, 2026, 5:21 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 694.47K
- P/E ratio
- —
- Dividend yield
- 1.11%
- 52-week range
- $65.65 – $82.02
- Volume
- 1.11K
- Avg. volume
- 342
Price performance · GSKH
GSKH price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
GSKH closed at $70.91 after 20 trading sessions, up 5.54% for the selected period.
- Last close
- $70.91
- Period change
- +5.54%
- Period low
- $65.79
- Period high
- $71.96
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $70.00 | $70.9092 | $70.00 | $70.9092 | 1.11K |
| Nov 5, 2026 | $70.67 | $70.67 | $70.4622 | $70.4622 | 233 |
| Nov 4, 2026 | $70.39 | $71.2768 | $70.39 | $71.2768 | 111 |
| Nov 3, 2026 | $69.17 | $69.17 | $68.3443 | $68.3443 | 213 |
| Nov 2, 2026 | $69.24 | $69.24 | $68.9481 | $68.9481 | 113.09 |
| Oct 30, 2026 | $69.50 | $69.84 | $69.4931 | $69.4931 | 276 |
| Oct 29, 2026 | $68.20 | $68.4506 | $68.20 | $68.4506 | 223 |
| Oct 28, 2026 | $69.16 | $69.47 | $68.7883 | $68.7883 | 264 |
| Oct 27, 2026 | $72.00 | $72.00 | $71.9616 | $71.9616 | 126 |
| Oct 26, 2026 | $71.88 | $72.12 | $71.82 | $71.9426 | 331 |
| Oct 23, 2026 | $70.78 | $71.3699 | $70.78 | $71.3699 | 280.02 |
| Oct 22, 2026 | $70.80 | $71.90 | $70.80 | $71.8562 | 209.55 |
| Oct 21, 2026 | $70.40 | $70.69 | $70.3866 | $70.3866 | 318 |
| Oct 20, 2026 | $70.35 | $71.74 | $70.07 | $71.11 | 921 |
| Oct 19, 2026 | $69.87 | $70.07 | $69.8585 | $69.8585 | 408 |
| Oct 16, 2026 | $70.06 | $70.18 | $69.8712 | $69.8712 | 507.02 |
| Oct 15, 2026 | $69.92 | $69.92 | $69.5531 | $69.5531 | 211 |
| Oct 14, 2026 | $67.45 | $68.3514 | $67.45 | $68.3514 | 483.04 |
| Oct 13, 2026 | $66.87 | $66.87 | $65.7878 | $65.7878 | 305 |
| Oct 12, 2026 | $67.1856 | $67.1856 | $67.1856 | $67.1856 | 3 |
Latest GSKH news
The latest Smart Investors Daily articles mentioning GSKH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GSKH research
Overview
Company profile and research snapshot.
Company profile
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of GSK plc (the “Company”). The series will not invest directly in the company. The fund is non-diversified.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
